# QUILT-3.076 (NCT04898543)

> QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: M-CENK plus nogapendekin alfa inbakicept (N-803)
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04898543
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Metastatic Solid Tumor
- Interventions: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B); N-803 (Cohort 2 part B); Apheresis collection of MNCs (part A)
- Enrollment: 50
- Primary outcome: Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.
- Primary outcome: Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.
- Primary outcome: Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.
- Primary outcome: Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (M-CENK Dose Number 1)
- Primary outcome: Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests
- Primary outcome: Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs

## Indexed commentary on QUILT-3.076 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=quilt-3-076-nct04898543
